about
Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patientsHigh plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.Cyclosporine markedly raises the plasma concentrations of repaglinide.Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjectsEffect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects.Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.Effect of rifampicin on the pharmacokinetics of pioglitazoneRofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.Effect of grapefruit juice on the bioactivation of prasugrelEffect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalaprilNeurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60-year-old Caucasian woman with ovarian carcinomaGrapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjectsA time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A.Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteersNo significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection.Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects.Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.Simvastatin pre-treatment improves survival and mitochondrial function in a 3-day fluid-resuscitated rat model of sepsis.Targeting matrix metalloproteinases with intravenous doxycycline in severe sepsis--A randomised placebo-controlled pilot trial.Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing.Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates.Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates.Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism.CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe.SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.The effects of intravenous lipid emulsion on hemodynamic recovery and myocardial cell mitochondrial function after bupivacaine toxicity in anesthetized pigs.Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide.Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions.Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite.Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo.Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.
P50
Q28195323-6AC0EF71-7A36-4AC3-9F75-1938E5DC896CQ28269517-9E110944-8D3F-46B3-8545-B8FDC11739DBQ31118020-2B0CC61D-E389-496F-8936-932FFA358E22Q34440964-34B1C995-F835-4FF5-B3EE-0A6EAD499760Q34561434-2D3EA7C3-0C72-4EEB-B74E-318B8093F1DDQ34592657-F0B90C3E-B71B-495E-8CC9-92E67AD4CF6EQ35826014-6E5B4D65-71CA-4B02-90E5-479EF749D193Q35826894-261D95B4-C8A8-45D9-9A6B-A33ADAD26D86Q35827146-1F0EC586-A28E-407A-A74B-6C27A823349FQ35827325-EE39BDFB-120A-4A97-8757-A2E3E128DEFCQ35827758-6C8A00EB-EA4A-44C8-88DF-A34F1C1EFAA4Q35846138-937EE060-269C-4E40-B7F1-7A93BF8682DCQ36243667-01107BBC-B333-4778-AFB6-09DF1C83090DQ36802118-80A00DD2-2CA9-4222-8B07-727CD3E9552FQ36948119-0EC3A79A-4478-4B5D-82ED-824F7026F160Q37219058-599AAC5D-0DA3-454D-827A-5EFF95A892EFQ37225099-97544E8C-5093-4B39-94F9-E6777A3EEB2CQ37399440-20DA3675-6F47-414A-BF13-2CF4557226F4Q37469455-1A1AB8A9-5F3E-4CFC-AB9D-10293AFBDD94Q37579953-8B300C2A-FC56-4F28-AB25-AF25C6BCBEAFQ37999939-CC38DC77-4201-4600-99ED-A5D92BD037E0Q38684505-34A1D0C2-8DE4-4118-8E75-97775908127AQ38933872-CDC07578-8DBC-4E2F-A25B-334C4E10E830Q40331469-BF8F25F3-BDC6-471A-8500-E2382E094F59Q40904610-3A01EBEE-68E6-402F-8C04-FEE9E41AD4FFQ41338181-7FA49BF5-4D71-4385-8BEC-ECF63EEB1E2FQ42283688-0130E9D8-88F9-400C-A916-3DF79A572CCFQ42283823-C6C50302-B18E-4070-A5A3-8F79BFACAF87Q43182515-C8EE9871-5F37-4408-96D1-E60DE5607F0FQ43272816-0E81BAF2-2267-4645-BB1F-BE10C4E2F81AQ43700650-26EBAFDE-E4BA-4C9C-B117-743AE58B9C9FQ44189515-54CC9E8D-99C1-423B-AAC4-95700F9777B7Q44391482-EAD9B104-DC8C-4785-BA57-8B26DF34EECDQ44502135-13CF8DE3-D86D-4A2A-AF7E-074D7FBD3EEAQ45062178-3BF4988F-1D77-4F86-A1FA-070755015A75Q46347800-B0D3CF42-84AB-4522-A410-4542056ED031Q46431899-D87F5877-C029-406B-ACF5-0769A77721B8Q46806917-8A49912E-11EB-4409-BEF1-3281A6AB5606Q46919666-1C209C03-F59E-4375-A7E2-7660FCF9917BQ46936376-D30579E2-EB79-4087-9513-0F79092B3942
P50
description
Finnish physician, professor o ...... icine (University of Helsinki)
@en
Fins medisch onderzoeker
@nl
suomalainen lääkäri, Helsingin ...... llisen lääketieteen professori
@fi
հետազոտող
@hy
name
Janne T Backman
@ast
Janne T Backman
@es
Janne T Backman
@nl
Janne T Backman
@sl
Janne Backman
@de
Janne Backman
@en
Janne Backman
@fi
Janne Backman
@sv
type
label
Janne T Backman
@ast
Janne T Backman
@es
Janne T Backman
@nl
Janne T Backman
@sl
Janne Backman
@de
Janne Backman
@en
Janne Backman
@fi
Janne Backman
@sv
altLabel
Janne T. Backman
@en
prefLabel
Janne T Backman
@ast
Janne T Backman
@es
Janne T Backman
@nl
Janne T Backman
@sl
Janne Backman
@de
Janne Backman
@en
Janne Backman
@fi
Janne Backman
@sv
P106
P1053
P-8682-2018
P21
P27
P31
P3829
P496
0000-0002-9577-2788
P569
1968-01-01T00:00:00Z